VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
19 hedge funds and large institutions have $29.7M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
12% more funds holding
Funds holding: 17 → 19 (+2)
11% more capital invested
Capital invested by funds: $26.8M → $29.7M (+$2.88M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.14M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$141K |
| 3 |
Neuberger Berman Group
New York
|
+$41.8K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$34K |
| 5 |
KA
Klingman & Associates
New York
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$8.29M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.48M |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$2.35M |
| 4 |
PA
Perceptive Advisors
New York
|
-$674K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$148K |
VBIV Hedge Fund Activity: Q2 2016 in Review
19 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q2 2016, worth a combined $29.7M — up 11% from $26.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VBIV positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.14M. The largest seller was Clarus Ventures, cutting an estimated $8.29M.
- 19 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q2 2016, up from 17 in Q1 2016.
- Funds reported $29.7M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q2 2016, up 11% quarter-over-quarter.
- 8 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q2 2016 and 6 closed out, a net change of +2 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q2 2016 was Vanguard Group, an estimated $1.14M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q2 2016 was Clarus Ventures, an estimated $8.29M sold.
Based on aggregated 13F filings for Q2 2016.